Safety Signals of CRS and ICANS With Tarlatamab in Relapsed Small Cell Lung Cancer: Insights From a Small Case Study
Juwhan Choi, Seunghun Lee, Sung Yong Lee · 2026
Read Safety Signals of CRS and ICANS With Tarlatamab in Relapsed Small Cell Lung Cancer: Insights From a Small Case Study by Juwhan Choi, Seunghun Lee, Sung Yong Lee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13590431.txt.
Description
Juwhan Choi, Seunghun Lee, and Sung Yong Lee published a case study in 2026 on the safety of a new immune drug for relapsed small cell lung cancer. The drug links T cells to a target on the tumor, and its known risks include a feverish immune surge and a brain side effect. Real-world reports on how often these occur were scarce.
The team reviewed eleven patients treated through an access program over about a year and a half. Tumors shrank or held steady in most patients. The immune surge appeared in seven patients but stayed mild and never needed intensive care. One patient developed a severe brain episode and recovered fully. Blood patterns during surges may help staff spot them early.
Catalog record
| CREATOR | Juwhan Choi, Seunghun Lee, Sung Yong Lee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |